Fredun Pharmaceuticals Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Fredun Pharmaceuticals reported Q1 FY27 standalone total income of INR228.25 crores, up 90.44% year-on-year, with EBITDA of INR32.78 crores and net profit of INR13.17 crores. Management attributed part of the growth to booking additional customer orders at older prices ahead of a price increase in the prior quarter. Management also discussed growth plans across its new-age brands, GX division, pet care business including the Wagr platform, working capital, inventory days, and capex for the coming years.
Fredun Pharmaceuticals reported Q4 FY26 total income of INR213 crores, up 27.27% year-on-year, with EBITDA of INR29.13 crores and net profit of INR11.07 crores. For FY26, total income reached INR639.12 crores, a 40.08% year-on-year increase, with EBITDA of INR94.79 crores and net profit of INR33.21 crores. Management discussed growth plans for its hormonal, anti-aging, mobility, and pet care businesses, and addressed questions on raw material costs, finance costs, margins, and working capital.